Pfizer Stock News

Pfizer and BioNTech said they expect to complete the EUA submission in the coming days. The post Pfizer, BioNTech seek emergency authorization for COVID-19 vaccine for kids under 5 years of age appeared first on The Arabian Stories News .

Pfizer and BioNTech said Tuesday they are seeking emergency authorization from US health regulators for use of their Covid vaccine for children aged over six months and under five years.

A local pediatrician spoke with Eyewitness News on Tuesday night about what she wants to see before the approval is given.

A pharmaceutical giant wants to immunize younger children against the COVID-19 disease. Pfizer recently requested emergency use authorization from the U.S. Food and Drug Administration (FDA) to vaccinate children aged between six months and 5 years old. The drug maker claims the Pfizer-BioNTech COVID-19 shot is urgently needed across the United States due to more []

If approved, Pfizers vaccine would be the first available for American children under the age of five Pfizer and BioNTech announced on Tuesday that they were seeking approval from the US Food and Drug Administration (FDA) to vaccinate children as young as 6 months old against Covid-19. If given approval, children aged six months to

US regulators are considering the first COVID-19 vaccine for children under the age of 5, the only age group not yet eligible for the shots, after Pfizer Inc and BioNTech SE began the regulatory approval process on Tuesday, February 1. A decision is expected as soon as this month. The companies said they began submitting data for an emergency use authorization even though they did not meet a key target in their clinical trial of 2- to 4- year olds. They are submitting the data at the request of the US Food and Drug Administration in order to address an urgent public health need in the age group, they said. The arrival of a vaccine for younger children could help harried parents who have had to contend with quarantines and closures of pre-schools and daycare centers. Having a safe and effective vaccine available for children in this age group is a priority, acting FDA Commissioner Janet Woodcock said. She said the agency asked for the application because of the recent Omicron surge. The FDA said an outside committee of expert advisers would meet on February 15 to discuss the authorization.

Pfizer seeking the OK for a vaccine for the under-5 age group is "a really good thing I''m really hopeful this helps families start planning for a more normal future."

For kids under 5, Pfizer''s study is giving participants two shots three weeks apart, followed by a third dose at least two months later. The company is testing whether the youngsters produce antibody levels similar to those known to protect teens and young adults.

Pfizer and BioNTech have sought approval from the US Food and Drug Administration (FDA) to vaccinate children under five against Covid-19 Read Full Article at RT.com

Taibbi: The British Medical Journal Story That Exposed Politicized "Fact-Checking" Authored by Matt Taibbi via TK News , In February of 2010, the New York Times released a front-page story entitled, Research Ties Diabetes Drug to Heart Woes . The lede read: Hundreds of people taking Avandia, a controversial diabetes medicine, needlessly suffer heart attacks and heart failure each month, according to confidential government reports that recommend the drug be removed from the market. The Times piece quoted an internal F.D.A. report that said the GlaxoSmithKline diabetes drug Avandia, also known as Rosiglitazone, was linked to 304 deaths in 2009, adding the conclusion of the two doctors who authored the report: Rosiglitazone should be removed from the market. The story was released in advance of a Senate Finance Committee study that produced a series of damning internal documents, including one in which an FDA safety officer expressed concern that Avandia presented such serious cardiovascular risks that the safety of the study itself cannot be assured, and is not acceptable. One of the chief investigators on that study was Paul Thacker, at the time a committee aide under Iowa Republican Chuck Grassley.

The Food and Drug Administration asked to review Pfizers data on two doses now, while the company continues to assess whether three doses would be more effective.

In an extraordinary move, US health authorities have urged Pfizer to apply earlier than it had planned.

Pfizer Inc and BioNTech SE on Tuesday said they have begun submitting data to US regulators seeking emergency use authorisation (EUA) of their COVID-19 vaccine for children under age 5, despite weaker-than-expected immune responses in their clinical trial of 2- to 4-year-olds. The companies said they

In a Tuesday press release, the FDA said the agency pushed Pfizer and BioNTech to submit the application given the ongoing Omicron surge.